GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GeneDx Holdings Corp.
GeneDx, spun off from OPKO Health, specializes in genetic testing for rare diseases. Its stock price reflects the potential of genomics in diagnostics, but also the intense competition and difficulty of monetizing this rapidly evolving field of medicine.
Share prices of companies in the market segment - Dna
GeneDx, a spinoff from OPKO Health, specializes in genetic testing for rare diseases. We classify it as part of the DNA sector, and the chart below reflects the overall dynamics of this market segment.
Broad Market Index - GURU.Markets
GeneDx is a leader in genomic and exome diagnostics, providing tests for rare genetic diseases. As a component of the GURU.Markets index, the company is at the forefront of genetic medicine. The chart below represents the entire market. See how GeneDx shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
WGS - Daily change in the company's share price GeneDx Holdings Corp.
The volatility of GeneDx, a genetic testing company, reflects the state of the genomics sector. Change_co reflects sensitivity to scientific breakthroughs and changes in health insurance. This metric is key to analyzing the innovative diagnostics sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
GeneDx Holdings Corp. is a company specializing in genetic testing. This chart highlights the sector's high volatility. Comparison with WGS's performance helps assess how sensitive its business is to insurance rates and competition.
Daily change in the price of a broad market stock, index - GURU.Markets
GeneDx is a leader in genomic testing for the diagnosis of rare inherited diseases. This sector is one of the most advanced and volatile in biotech. The chart below reflects the extreme fluctuations typical of this industry.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GeneDx Holdings Corp.
GeneDx is a leader in genetic testing. Its year-over-year performance reflects rapid growth in testing volumes and investor confidence in the potential of its technologies for early disease diagnosis. The chart below illustrates the history of this science-intensive business.
Annual dynamics of market capitalization of the market segment - Dna
GeneDx Holdings Corp. specializes in genomic and exome sequencing for the diagnosis of rare diseases. Its data and analytics are key to personalized medicine. The chart shows how its scientific leadership and competition in the rapidly evolving field of genetics influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GeneDx, a genetic testing company, is betting on the future of personalized medicine. Its stock price is volatile and depends on technological breakthroughs, testing volumes, and insurance coverage. The chart isn't about economics, but rather how quickly genomics will be integrated into standard medical practice.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GeneDx Holdings Corp.
GeneDx, a genetic testing company, is valued based on its operational success. Monthly fluctuations on the chart reflect the volume of tests performed, insurance reimbursement rates, and progress in leveraging its vast database to develop new diagnostic solutions.
Monthly dynamics of market capitalization of the market segment - Dna
GeneDx uses genomic analysis to diagnose rare inherited diseases, helping doctors and patients find answers where none existed before. This is the cutting edge of personalized medicine. The graph below shows the overall dynamics of the genetic research sector, which is rapidly evolving thanks to technological breakthroughs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Genetic diagnostics stocks are betting on the future of personalized medicine. The chart below shows investors' overall risk appetite. Is GeneDx Holdings moving in sync with the market's growth, or are its scientific breakthroughs creating their own trend?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GeneDx Holdings Corp.
GeneDx, a genetic testing company, is at the forefront of personalized medicine. Its weekly stock price reflects scientific breakthroughs in genomics, changes in insurance coverage for testing, and news of partnerships with pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Dna
The genetic testing sector, where GeneDx operates, is at the forefront of medicine and technology. The chart below reflects the general sentiment in this innovative niche. It allows one to assess how GeneDx's strategic focus and database impact its competitive position relative to other diagnostic companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
GeneDx is a company specializing in genomic and exome diagnostics. Its business is at the forefront of medical science. The chart will show how much its stock price is driven by scientific breakthroughs and testing implementation, rather than by general stock market trends.
Market capitalization of the company, segment and market as a whole
WGS - Market capitalization of the company GeneDx Holdings Corp.
GeneDx's market capitalization reflects investors' bets on the future of genetic testing. The chart shows how the market values its ability to analyze genomes to diagnose rare diseases and hereditary cancers. Its volatility reflects the intense competition and difficulty of monetizing this cutting-edge field of medicine.
WGS - Share of the company's market capitalization GeneDx Holdings Corp. within the market segment - Dna
GeneDx Holdings aims to capture a significant share of the genetic testing and data analysis market. Its market capitalization reflects the potential of its platform for diagnosing rare diseases and providing valuable information for drug development.
Market capitalization of the market segment - Dna
This graph shows the total value of the entire genetic diagnostics sector. For GeneDx, a leader in genome analysis for rare diseases, this line represents the future of medicine. The rising graph reflects how quickly genetic testing is becoming the standard for diagnostics and personalized treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
GeneDx (WGS) is a leader in genomic diagnostics, helping to identify rare diseases. Its market capitalization reflects the potential of genetic information for the future of medicine. This market share is determined by the potential of deciphering the code of life to save lives.
Book value capitalization of the company, segment and market as a whole
WGS - Book value capitalization of the company GeneDx Holdings Corp.
GeneDx Holdings specializes in genetic testing, and its book value is its scientific and technological capital. This includes cutting-edge laboratories, DNA sequencers, and vast genetic databases (an intangible asset). How has the value of this foundation for personalized medicine changed? The chart below shows.
WGS - Share of the company's book capitalization GeneDx Holdings Corp. within the market segment - Dna
GeneDx Holdings Corp. is a leader in genomic diagnostics, and its expertise is backed by powerful laboratories. The company's balance sheet reflects the value of its high-tech sequencing centers, equipped with state-of-the-art equipment. The chart shows its share of the physical infrastructure for genetic research.
Market segment balance sheet capitalization - Dna
GeneDx is a leader in genomic diagnostics. Compared to the capital-intensive healthcare sector, its model is knowledge-intensive. The industry's asset value reflects the value of hospitals. GeneDx, on the other hand, invests in cutting-edge laboratories and databases, which are its core assets.
Book value of all companies included in the broad market index - GURU.Markets
GeneDx Holdings is a leader in genomic diagnostics, with assets including a vast database and laboratories. Its book value comes from its high-tech DNA sequencing equipment and computing power. The chart shows the material foundation upon which technologies for understanding rare diseases are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GeneDx Holdings Corp.
GeneDx owns laboratories, but its main asset is one of the world's largest genomic databases. The chart shows the market premium paid for this unique information resource, which is key to understanding and treating rare diseases. This is a value assessment of the data, not the equipment.
Market to book capitalization ratio in a market segment - Dna
GeneDx Holdings specializes in genetic and genomic testing for the diagnosis of rare diseases. Its main asset is its vast database and expertise in genome interpretation. The chart shows how the market values this unique information asset, not the cost of laboratory equipment.
Market to book capitalization ratio for the market as a whole
GeneDx Holdings, formerly Sema4, focuses on genomic and clinical data analysis for diagnostics of rare diseases and oncology. The company's value lies in its massive database and interpretation platform. This chart shows the overall valuation, but how does the market attempt to value a company that uses genomics for personalized medicine?
Debts of the company, segment and market as a whole
WGS - Company debts GeneDx Holdings Corp.
GeneDx operates in the field of genomic research, which requires ongoing investment in laboratory equipment and computing power. For a growth-stage company, debt capital can serve as a bridge to funding operations and scaling testing volumes until stable profitability is achieved.
Market segment debts - Dna
GeneDx Holdings, formerly known as Sema4, specializes in genomic and clinical data analysis for disease diagnosis. This cutting-edge field of medicine requires ongoing investment in technology and research. This chart illustrates how the company finances its activities in the competitive and rapidly evolving genetic testing industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GeneDx Holdings Corp.
GeneDx Holdings, formerly known as Sema4, specializes in genomic and clinical data analysis. This chart shows the company's financial position during its business transformation. For a genetic diagnostics company, which requires significant investment in technology and research, managing capital and debt is critical to achieving profitability.
Market segment debt to market segment book capitalization - Dna
Genetic testing and diagnostics, GeneDx's specialty, is a knowledge-intensive industry that requires ongoing investment in technology and research. This chart shows the overall debt burden in the healthcare sector. It helps understand how GeneDx finances its cutting-edge developments and how its financial model compares to other diagnostic companies.
Debt to book value of all companies in the market
This chart reflects the average "credit appetite" of the entire economy. GeneDx, which operates in the field of genetic diagnostics, requires constant investment in research and equipment. A comparison with the overall market allows us to assess how capital-intensive this industry, at the intersection of medicine and IT, is compared to the average publicly traded company.
P/E of the company, segment and market as a whole
P/E - GeneDx Holdings Corp.
For GeneDx, a genetic testing company, this chart shows investor sentiment toward the prospects of personalized medicine. The multiple reflects confidence in the growing demand for diagnostics for rare diseases and hereditary conditions, as well as the company's ability to monetize its unique data and technologies.
P/E of the market segment - Dna
Genetic testing, the business of GeneDx, is at the forefront of medicine. This chart shows the average valuation for life sciences companies. It helps us understand how investors view GeneDx and its vast genomic databases as a key asset for future discoveries and diagnostics of rare diseases.
P/E of the market as a whole
GeneDx Holdings Corp. is a leader in genomic and clinical diagnostics, providing physicians with diagnostic information for rare diseases and inherited cancers. This chart reflects overall investor interest in the healthcare and biotech sectors. It helps understand whether the WGS valuation reflects belief in the future of personalized medicine or general market trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GeneDx Holdings Corp.
GeneDx, formerly known as Sema4, specializes in genomic and clinical data analysis for disease diagnosis and treatment. This chart reflects market expectations for the future growth of personalized medicine. It demonstrates investor confidence that genetic testing will become standard in healthcare, driving demand for the company's services.
%20P%2FE%20GeneDx%20Holdings%20Corp.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GeneDx-Holdings-Corp.&v=1772513774258 "Chart of the company's future (projected) P/E GeneDx Holdings Corp.")
Future (projected) P/E of the market segment - Dna
GeneDx Holdings, formerly known as Sema4, is a leader in genomic and clinical data analysis, providing insights for the diagnosis and treatment of diseases. This chart shows how analysts estimate its future revenue compared to other companies in the DNA diagnostics sector, reflecting its belief in the future of personalized medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513774259 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
GeneDx Holdings is a leader in genomic diagnostics, helping to identify rare genetic diseases. The company's business is at the forefront of medicine, and its growth is driven by the rapid adoption of genetic testing. In line with overall market forecasts, GeneDx is a story of a technological breakthrough in healthcare.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513774263 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GeneDx Holdings Corp.
GeneDx Holdings Corp. (WGS) specializes in genetic and genomic testing, helping diagnose rare diseases. The company's profits depend on the number of tests performed and reimbursement from insurance companies. This chart shows how successfully the company commercializes cutting-edge science, turning genetic data into actionable medical information.
Profit of companies in the market segment - Dna
GeneDx, formerly Sema4, is a leader in genomic and clinical diagnostics. The company uses data to improve disease prognosis and treatment. This chart reflects the overall dynamics of the genetic research sector, where scientific breakthroughs and big data analysis are ushering in a new era of personalized medicine and high potential profitability.
Overall market profit
GeneDx Holdings specializes in genetic testing for the diagnosis of rare diseases. Demand for its services is growing thanks to scientific advances. However, widespread adoption depends on insurance coverage. The overall economic situation, reflected in the chart, influences the generosity of insurance plans and healthcare budgets.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GeneDx Holdings Corp.
GeneDx Holdings Corp. is a leader in genomic and clinical data analysis, helping doctors and patients make more informed healthcare decisions. The company is at the intersection of medicine and big data. This chart represents analyst consensus forecasts for future revenue, betting on a revolution in personalized medicine.
%20profit%20of%20the%20company%20GeneDx%20Holdings%20Corp.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GeneDx-Holdings-Corp.&v=1772513774282 "Graph of future (projected) profit of the company GeneDx Holdings Corp.")
Future (predicted) profit of companies in the market segment - Dna
GeneDx Holdings is a leader in genomic and exome diagnostics, providing information for the detection of rare diseases and inherited cancers. The company's technologies help doctors make accurate diagnoses. This chart shows revenue projections for the healthcare and biotech sectors, providing context for assessing GeneDx's potential in the revolutionary field of genetic research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513774298 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
GeneDx Holdings specializes in genetic and genomic testing, assisting in the diagnosis of rare diseases. Demand for its services is driven by advances in medicine and the pursuit of personalized treatments, rather than the state of the economy. This makes its business non-cyclical and dependent on healthcare trends rather than general corporate profit forecasts.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513774309 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GeneDx Holdings Corp.
GeneDx Holdings specializes in genetic testing and diagnostics. This chart illustrates how the market values its revenue in the innovative field of genomics. This valuation reflects the growth potential of data-driven diagnostics and the future of personalized medicine.
P/S market segment - Dna
GeneDx Holdings Corp. specializes in genetic and genomic testing, providing information for the diagnosis and treatment of rare diseases. This chart shows the average revenue estimate for the diagnostics sector. It helps understand how investors view GeneDx's growth potential, driven by the growing demand for personalized medicine and genetic testing.
P/S of the market as a whole
GeneDx Holdings, formerly known as Sema4, is a leader in genomic and clinical data analysis, providing physicians and patients with critical diagnostic information. Their business is big data in medicine. This chart provides an overview of market revenue estimates, which can be used to assess the potential of WGS and investor expectations for a revolution in healthcare.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GeneDx Holdings Corp.
GeneDx Holdings is a leader in genomic and exome sequencing, providing diagnostic tests for rare inherited diseases. Its estimated future revenue, shown in the graph, depends on the number of tests performed and their reimbursement by insurance companies. Growth is driven by the development of personalized medicine.
%20P%2FS%20GeneDx%20Holdings%20Corp.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GeneDx-Holdings-Corp.&v=1772513774358 "The graph of the company's future (projected) P/S GeneDx Holdings Corp.")
Future (projected) P/S of the market segment - Dna
GeneDx Holdings is a leader in genomics, providing genetic testing for the diagnosis of rare and inherited diseases. The company is at the forefront of personalized medicine. This chart shows how the market views its future testing volumes and the value of its data compared to the rapidly growing diagnostics sector.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513774382 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
GeneDx Holdings specializes in genomic and exome sequencing for the diagnosis of rare diseases. This graph, reflecting overall economic confidence, influences healthcare budgets and insurers' willingness to cover expensive genetic tests. Economic growth facilitates expanded patient access to the advanced diagnostic technologies offered by GeneDx.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513774461 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GeneDx Holdings Corp.
GeneDx Holdings, formerly Sema4, specializes in genomic and clinical data analysis for the diagnosis of rare diseases and oncology. This chart reflects revenue from genetic testing and data analysis for patients, physicians, and pharmaceutical companies. It demonstrates how cutting-edge genomics is being transformed into commercial diagnostic services.
Sales of companies in the market segment - Dna
GeneDx Holdings Corp. (formerly Sema4) specializes in genomic and clinical data analysis to improve diagnostics and treatment. The company's business can be divided into rare disease diagnostics and reproductive health segments. This chart shows revenue from one of these segments, reflecting the demand for genetic testing in a specific medical area.
Overall market sales
GeneDx Holdings Corp. (WGS) specializes in genetic testing for the diagnosis of rare diseases and inherited conditions. Its business operates at the intersection of healthcare and high technology. Demand for the company's services is driven not by the economic cycle, but by advances in genomics and the pursuit of personalized medicine, which is transforming treatment approaches.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GeneDx Holdings Corp.
GeneDx (formerly Sema4) is a company specializing in genomic and clinical data analysis to improve diagnostics and treatment. Its revenue forecast depends on the number of genetic tests conducted and its ability to sell its analytical solutions to pharmaceutical companies. This reflects the growing role of genetics in modern medicine.
%20sales%20of%20the%20company%20GeneDx%20Holdings%20Corp.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GeneDx-Holdings-Corp.&v=1772513774533 "Schedule of future (projected) sales of the company GeneDx Holdings Corp.")
Future (projected) sales of companies in the market segment - Dna
GeneDx Holdings Corp. provides genomic and exome sequencing services for the diagnosis of rare diseases. This chart shows revenue expectations for the genetic diagnostics sector. It reflects analysts' views on the pace of clinical adoption of genetic testing, a key growth driver for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513774548 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
GeneDx specializes in genetic testing. Demand for its services depends on healthcare budgets and the willingness of patients and physicians to use advanced diagnostics. This overall sales forecast chart reflects the economic situation that impacts the healthcare system's ability to implement innovative tests.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513774600 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GeneDx Holdings Corp.
GeneDx Holdings Corp. is a leader in genomic and clinical diagnostics, providing data analysis services for the detection of rare diseases. This chart shows the company's financial trajectory, with significant investments in technology and data processing aimed at creating a long-term profitable business model in the field of personalized medicine.
Market segment marginality - Dna
GeneDx Holdings, formerly Sema4, specializes in genomic and clinical data analysis for the diagnosis of rare diseases and hereditary cancers. This is a knowledge-intensive business requiring advanced technology and expertise. This chart shows how the company monetizes its unique capabilities in genetic testing and data analysis compared to other healthcare players.
Market marginality as a whole
GeneDx Holdings Corp. specializes in genetic and genomic testing, helping diagnose rare diseases. The company's profitability depends on the number of tests performed and reimbursement by insurance companies. This chart reflects overall profitability, but for WGS, breakthroughs in genetics and personalized medicine are the primary growth drivers.
Employees in the company, segment and market as a whole
Number of employees in the company GeneDx Holdings Corp.
GeneDx, formerly Sema4, specializes in genetic testing and data analysis. This chart shows the team of scientists, genetic counselors, and lab technicians. The headcount changes reflect the company's strategic changes, including a focus on rare disease diagnostics and a shift away from less profitable areas.
Share of the company's employees GeneDx Holdings Corp. within the market segment - Dna
GeneDx Holdings is a leader in genomic diagnostics, helping to identify rare diseases. Its work requires a large team of geneticists, laboratory technicians, and bioinformaticians. This reflects its scale in this cutting-edge field of medicine, where human intelligence analyzes complex data.
Number of employees in the market segment - Dna
GeneDx Holdings specializes in genetic and genomic testing for the diagnosis of rare diseases. This chart reflects employment in the DNA diagnostics sector. The rapid growth in the number of geneticists and laboratory technicians in this field reflects the revolution in personalized medicine and the growing recognition of the importance of genetic information for treatment.
Number of employees in the market as a whole
GeneDx Holdings specializes in genetic testing. The adoption of advanced diagnostic methods is linked to overall healthcare spending. A strong economy, symbolized by this graph, supports investment in innovation and ensures broad insurance coverage for such tests, expanding the market for GeneDx.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GeneDx Holdings Corp. (WGS)
GeneDx Holdings is a leader in genomic testing and data analysis. It's a knowledge-intensive business where value is created at the intersection of biology and IT. The high market capitalization per employee in this chart indicates that the market highly values its unique databases and the intellectual capital of its geneticists and bioinformaticians, who are capable of interpreting complex data.
%20of%20the%20company%20GeneDx%20Holdings%20Corp.%20(WGS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GeneDx-Holdings-Corp.-WGS&v=1772513774932 "Chart of market capitalization per employee (in thousands of dollars) of the company GeneDx Holdings Corp. (WGS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
GeneDx (WGS) is a genomics company specializing in exome sequencing for diagnosing rare diseases. It's a research-intensive, laboratory-based business. This chart shows the market value per employee, reflecting the market's confidence in its technology platform and growth.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513775028 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
GeneDx Holdings Corp. (WGS) is a company specializing in genetic and genomic testing for the diagnosis of rare diseases. Their business operates at the intersection of medicine and big data. The chart reflects how the market perceives the scientific potential and technology platform of a team of geneticists and bioinformaticians.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513775079 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GeneDx Holdings Corp. (WGS)
GeneDx (WGS) is a leader in genomic diagnostics, specializing in sequencing and data analysis for the detection of rare diseases. It's a high-tech laboratory business. This chart demonstrates how effectively their team of geneticists, laboratory technicians, and bioinformatics specialists can process tests and interpret complex data, turning science into a commercially viable diagnostic service.
%20Chart%20GeneDx%20Holdings%20Corp.%20(WGS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GeneDx-Holdings-Corp.-WGS&v=1772513775138 "Company Profit Per Employee (in thousands of dollars) Chart GeneDx Holdings Corp. (WGS)")
Profit per employee (in thousands of dollars) in the market segment - Dna
GeneDx (WGS) is a "genetic" lab specializing in "rare" diseases (sequencing). This chart shows the benchmark for "Dna" (Lab). In this sector, the benchmark is likely *negative*. It's a "B2B service," where the profit per scientist is "eaten away" by the high cost of sequencing and pressure from insurers.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513775170 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
GeneDx (WGS) is a company specializing in genomic testing. They use next-generation sequencing to diagnose rare genetic diseases and hereditary cancers. This chart, showing average profit per employee, provides context. It helps understand how profitable the genetic diagnostics sector, which relies on scientists and lab technicians, is relative to its workforce.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513775201 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GeneDx Holdings Corp. (WGS)
GeneDx Holdings specializes in genomic and exome sequencing for the diagnosis of rare diseases. This chart reflects the value of genetic information. The growth in revenue per employee, primarily from scientists and lab technicians, reflects the growing acceptance of genetic testing in medicine and the company's ability to process ever-increasing samples.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GeneDx-Holdings-Corp.-WGS&v=1772513775247 "Sales chart per company employee GeneDx Holdings Corp. (WGS)")
Sales per employee in the market segment - Dna
GeneDx (WGS) is a company specializing in genetic testing and genomic data analysis, particularly for the diagnosis of rare diseases. This chart shows revenue per employee (laboratory technician, geneticist). Comparisons with the diagnostics sector help assess how automated and efficient their labs are in terms of test processing compared to competitors.
Sales per employee for the market as a whole
GeneDx (WGS) is a leader in genomic testing. They analyze DNA for the diagnosis of rare hereditary diseases and oncology. They are a high-tech laboratory business. This chart shows the company's revenue per employee (geneticist, lab technician, data scientist). This is a measure of the efficiency of their complex and expensive diagnostic processes.
Short shares by company, segment and market as a whole
Shares shorted by company GeneDx Holdings Corp. (WGS)
GeneDx (WGS) is a genetic testing company. They help diagnose rare diseases and hereditary cancers by analyzing the genome. This is a cutting-edge field of medicine, but it faces challenges with insurance reimbursement. This chart shows the number of people who doubt GeneDx can make a profit.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GeneDx-Holdings-Corp.-WGS&v=1772513775336 "Short Shares Chart for the Company GeneDx Holdings Corp. (WGS)")
Shares shorted by market segment - Dna
GeneDx (WGS) specializes in genomic and exome sequencing for the diagnosis of rare diseases and inherited conditions. They help doctors discover the genetic causes of illnesses. This chart shows the odds against the genetic diagnostics sector. It reflects concerns about competition, pricing pressure, and changes in insurer reimbursement policies.
Shares shorted by the overall market
GeneDx (WGS) is a genetic testing company. It's a growth stock. This Short_All chart is a fear meter. When it rises, it signals risk aversion. Investors are dumping money-losing growth stocks like WGS in favor of profitable companies, despite their scientific potential.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GeneDx Holdings Corp. (WGS)
GeneDx (formerly Sema4) specializes in genomic testing and data analysis. Business depends on physician acceptance of tests and reimbursement rates. This chart for WGS above 70 may reflect optimism for growth. Below 30 is often associated with reimbursement issues, competition, or unprofitability.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GeneDx-Holdings-Corp.-WGS&v=1772513775404 "RSI 14 indicator chart for the company's stock GeneDx Holdings Corp. (WGS)")
RSI 14 Market Segment - Dna
GeneDx Holdings (WGS) is a leader in genomic sequencing for diagnosing rare diseases. The RSI_14_Seg for "Dna" (genomics) shows the "temperature" in this cutting-edge sector. The chart helps us understand: is WGS's growth a sign of recognition for its platform, or is the entire sector overheated by anticipation of new discoveries?
RSI 14 for the overall market
GeneDx, a genetic sequencing specialist, sees this graph as a reflection of the healthcare system's readiness for innovation. During periods of market euphoria, hospitals and insurance companies are more willing to pay for expensive but cutting-edge genetic tests. During periods of panic and economic downturn, the focus shifts to cost cutting, which slows the adoption of new diagnostic technologies.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast WGS (GeneDx Holdings Corp.)
GeneDx Holdings is a leader in genomic testing. The company analyzes exomes and genomes to diagnose rare diseases and hereditary cancers, building a massive genomic database. This chart shows the average analyst forecast. Their target prices are based on testing volumes, insurance reimbursement levels, and the potential for monetization of their data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-WGS-GeneDx-Holdings-Corp.&v=1772513775519 "A chart showing analyst consensus forecasts for the expected stock price. WGS (GeneDx Holdings Corp.)")
The difference between the consensus estimate and the actual stock price WGS (GeneDx Holdings Corp.)
GeneDx (WGS) is a company specializing in genetic sequencing and data analysis for the diagnosis of rare diseases and inherited disorders. This chart shows their data valuation. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their genomic analytics platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-WGS-GeneDx-Holdings-Corp.&v=1772513775571 "A chart showing the difference between the consensus forecast and the actual stock price. WGS (GeneDx Holdings Corp.)")
Analyst consensus forecast for stock prices by market segment - Dna
GeneDx (WGS) is a company specializing in genetic sequencing and data analysis, particularly in the areas of rare diseases and cancer diagnostics. This chart shows analysts' overall expectations for the entire DNA analysis sector. It reflects whether experts believe in a boom in personalized medicine or consider the market overheated.
Analysts' consensus forecast for the overall market share price
GeneDx Holdings Corp. (WGS) specializes in genomic testing, providing physicians and patients with diagnostic data for rare diseases and hereditary cancers. This chart shows the company's overall risk appetite. For GeneDx, which operates in the cutting-edge but capital-intensive field of genetics, overall market optimism is important for funding research and expanding its paying customer base.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GeneDx Holdings Corp.
GeneDx (WGS) is a leader in genomic diagnostics. They specialize in exome sequencing—deep DNA analysis to detect rare inherited diseases and aid in diagnosis. This chart evaluates their scientific database and reflects their ability to transform complex genetic tests into clinically relevant information for physicians and pharmaceutical companies.
AKIMA Market Segment Index - Dna
GeneDx (WGS) is a leader in rare genetics, specializing in the most sophisticated genetic tests (exome/genome sequencing) for diagnosing rare (orphan) diseases. This aggregate metric evaluates companies. The chart shows the sector average. This benchmark: how does GeneDx's high-tech (complex genetics) expertise differentiate it from the average competitor?
The AKIM Index for the overall market
GeneDx is a genetic detective. The company is a leader in sequencing (reading DNA) for diagnosing rare hereditary diseases. This chart, reflecting the market average, is a backdrop. It helps assess how this growth story in the protective healthcare sector compares to the overall macroeconomic trends impacting markets.
